Immune cells targeting NF or schwannomatosis tumors
Part of Cancer clinical trials.
This trial tests a new immunotherapy using your own immune cells trained to target specific markers on your tumors. It is for people with neurofibromatosis or schwannomatosis whose tumors have recently grown.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 1 year old.
- You must have neurofibromatosis or schwannomatosis with at least one measurable tumor that has grown in the past year.
- Your tumor cells must test positive for certain markers that the immune cells can target.
- You must have adequate blood cell counts, kidney and liver function, and be in generally stable health.
- You cannot have had other cell therapy in the past year, or be pregnant, or have uncontrolled infections or heart/lung problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new therapy where your immune cells are modified to better recognize and attack breast cancer cells. It is for people with advanced or recurrent breast cancer that has certain markers on the tumor cells.
This trial tests a new immune cell therapy (CAR-T) for people whose neuroblastoma or desmoplastic small round cell tumor has returned or not responded to standard treatments. The goal is to see if this therapy is safe and can help shrink or control the cancer.
This trial studies targeted medicines in people with neurofibromatosis type 2 (NF2) who have growing tumors on scans. The goal is to slow tumor growth and improve symptoms by testing different drug combinations in separate study groups.
This study looks at new medicines for people with NF2-related schwannomatosis (NF2-SWN), a condition that causes tumors on nerves. It aims to track how tumors grow over time and test potential treatments.
This trial tests a drug called selumetinib for people with a rare genetic condition called NF2-related schwannomatosis, which causes non-cancerous tumors on nerves. The study focuses on shrinking or slowing the growth of these tumors, especially those affecting hearing, and is for patients who cannot have surgery or choose not to.
This trial tests a combination of two drugs (Luvometinib and Serplulimab) for people with NF2 (Neurofibromatosis type 2) who have growing brain tumors (vestibular schwannoma or meningioma) that cannot be safely removed with surgery. The goal is to see if this drug combination can shrink or slow the growth of these tumors.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.